Aerie Pharmaceuticals Company Profile (NASDAQ:AERI)

About Aerie Pharmaceuticals

Aerie Pharmaceuticals logoAerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's primary product candidates are Rhopressa and Roclatan. Its product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Rhopressa is a once-daily eye drop and a triple-action netarsudil ophthalmic solution. The active ingredient in Rhopressa acts through the inhibition of both Rho Kinase (ROCK) and norepinephrine transporter (NET). Roclatan is a once-daily, quadruple-action product candidate and is a fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with glaucoma. The Company is engaged in conducting Phase III clinical trials for Rhopressa and Roclatan.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AERI
  • CUSIP:
Key Metrics:
  • Previous Close: $44.55
  • 50 Day Moving Average: $43.11
  • 200 Day Moving Average: $35.64
  • 52-Week Range: $33,382,000.00 - $10.82
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -18.04
  • P/E Growth: 0.00
  • Market Cap: $1.49B
  • Outstanding Shares: 33,382,000
  • Beta: 1.13
Profitability:
  • Return on Equity: -278.19%
  • Return on Assets: -52.67%
Debt:
  • Debt-to-Equity Ratio: 0.96%
  • Current Ratio: 18.21%
  • Quick Ratio: 18.21%
Additional Links:
Companies Related to Aerie Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Aerie Pharmaceuticals (NASDAQ:AERI) (?)
Ratings Breakdown: 13 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $56.85 (27.60% upside)

Analysts' Ratings History for Aerie Pharmaceuticals (NASDAQ:AERI)
Show:
DateFirmActionRatingPrice TargetDetails
2/24/2017Cowen and CompanyInitiated CoverageOutperform$70.00View Rating Details
2/17/2017Roth CapitalInitiated CoverageBuy$69.00View Rating Details
12/28/2016Needham & Company LLCReiterated RatingBuy$52.00View Rating Details
12/23/2016JMP SecuritiesReiterated RatingOutperform$49.00View Rating Details
12/20/2016Canaccord GenuityReiterated RatingBuy$50.00View Rating Details
11/10/2016AegisReiterated RatingBuy$63.00View Rating Details
10/28/2016Royal Bank of CanadaBoost Price TargetOutperform$48.00 -> $49.00View Rating Details
10/21/2016RBC Capital MarketsReiterated RatingOutperform$55.00View Rating Details
10/8/2016Cantor FitzgeraldReiterated RatingBuy$50.00View Rating Details
10/6/2016Stifel NicolausBoost Price TargetBuy$50.00 -> $55.00View Rating Details
10/6/2016Brean CapitalReiterated RatingBuy$48.00 -> $63.00View Rating Details
9/20/2016HC WainwrightInitiated CoverageBuy$66.00View Rating Details
9/13/2016Raymond James Financial, Inc.Initiated CoverageOutperform$48.00View Rating Details
6/5/2015Piper Jaffray CompaniesReiterated RatingBuy$7.00 -> $9.00View Rating Details
3/24/2015MLV & Co.Reiterated RatingBuy$40.00View Rating Details
(Data available from 2/26/2015 forward)

Earnings

Earnings History for Aerie Pharmaceuticals (NASDAQ:AERI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2017($0.67)N/AView Earnings Details
11/2/2016Q316($0.67)($0.67)ViewN/AView Earnings Details
8/3/2016Q216($0.74)($0.72)ViewN/AView Earnings Details
5/2/2016Q116($0.64)($0.72)ViewN/AView Earnings Details
3/1/2016Q415($0.72)($0.64)ViewN/AView Earnings Details
11/3/2015Q315($0.66)($0.56)ViewN/AView Earnings Details
8/5/2015Q215($0.70)($0.59)ViewN/AView Earnings Details
5/7/2015($0.62)($0.70)ViewListenView Earnings Details
3/2/2015Q414($0.46)($0.58)ViewN/AView Earnings Details
11/11/2014($0.40)($0.54)ViewN/AView Earnings Details
8/6/2014($0.34)($0.49)ViewN/AView Earnings Details
5/12/2014($0.35)($0.28)ViewN/AView Earnings Details
3/18/2014Q413($0.25)($0.62)ViewN/AView Earnings Details
12/4/2013Q313($0.25)($10.81)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aerie Pharmaceuticals (NASDAQ:AERI)
Current Year EPS Consensus Estimate: $-2.78 EPS
Next Year EPS Consensus Estimate: $-2.47 EPS

Dividends

Dividend History for Aerie Pharmaceuticals (NASDAQ:AERI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Aerie Pharmaceuticals (NASDAQ:AERI)
Insider Ownership Percentage: 8.77%
Institutional Ownership Percentage: 95.69%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/15/2017Geoffrey M DuykDirectorSell41,591$46.63$1,939,388.33View SEC Filing  
10/6/2016Foresite Capital Fund Ii, L.P.Major ShareholderSell50,000$40.34$2,017,000.00View SEC Filing  
7/22/2016Foresite Capital Fund Ii, L.P.Major ShareholderBuy250,000$17.50$4,375,000.00View SEC Filing  
4/15/2015Anand MehraDirectorSell425,000$33.64$14,297,000.00View SEC Filing  
1/8/2015Lifesciences Ii L.P. ClarusMajor ShareholderSell175,000$31.11$5,444,250.00View SEC Filing  
1/5/2015Lifesciences Ii L.P. ClarusMajor ShareholderSell23,620$30.86$728,913.20View SEC Filing  
12/29/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell80,724$30.05$2,425,756.20View SEC Filing  
12/23/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell49,704$30.36$1,509,013.44View SEC Filing  
12/22/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell49,441$30.36$1,501,028.76View SEC Filing  
11/25/2014Anand MehraDirectorSell800,000$26.00$20,800,000.00View SEC Filing  
11/25/2014Group Holdings (Sbs) Advis TpgInsiderSell1,300,000$25.97$33,761,000.00View SEC Filing  
7/10/2014Group Holdings (Sbs) Advis TpgMajor ShareholderSell1,000,000$25.17$25,170,000.00View SEC Filing  
7/9/2014Group Holdings (Sbs) Advis TpgMajor ShareholderSell500,000$25.05$12,525,000.00View SEC Filing  
5/22/2014Anand MehraDirectorSell323,932$16.00$5,182,912.00View SEC Filing  
5/22/2014Iv L.P. AcpMajor ShareholderSell300,000$16.00$4,800,000.00View SEC Filing  
5/16/2014Gerald CagleDirectorBuy1,854$15.07$27,939.78View SEC Filing  
10/30/2013Brian LevyInsiderBuy6,000$10.00$60,000.00View SEC Filing  
10/30/2013Iv L.P. AcpMajor ShareholderBuy110,000$10.00$1,100,000.00View SEC Filing  
10/30/2013Richard J RubinoCFOBuy10,000$10.00$100,000.00View SEC Filing  
10/30/2013Thomas A MitroCOOBuy5,000$10.00$50,000.00View SEC Filing  
10/30/2013Vicente Anido JrCEOBuy28,000$10.00$280,000.00View SEC Filing  
10/25/2013Anand MehraDirectorBuy285,000$10.00$2,850,000.00View SEC Filing  
10/25/2013Lifesciences Ii L.P. ClarusMajor ShareholderBuy321,000$10.00$3,210,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Aerie Pharmaceuticals (NASDAQ:AERI)
DateHeadline
seekingalpha.com logoCowen likes Aerie Pharma, sees 58% upside - Seeking Alpha - Seeking Alpha (NASDAQ:AERI)
seekingalpha.com - February 24 at 3:21 PM
marketexclusive.com logoAnalyst Activity – Cowen and Company Initiates Coverage On Aerie Pharmaceuticals (NASDAQ:AERI) With a Outperform - Market Exclusive (NASDAQ:AERI)
marketexclusive.com - February 24 at 10:26 AM
News IconTiny fraction of coveted IDA created jobs in Laois as the county remains rooted to bottom of league (NASDAQ:AERI)
www.leinsterexpress.ie - February 23 at 8:24 PM
News IconShares in Focus: Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) - The Standard (NASDAQ:AERI)
6milestandard.com - February 23 at 3:22 PM
News IconWatching Technical Positions on Aerie Pharmaceuticals Inc (AERI) - Baldwin Journal (NASDAQ:AERI)
baldwinjournal.com - February 23 at 3:22 PM
News IconShares in Review: Watching the Levels for Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) - Searcy News (NASDAQ:AERI)
searcysentinel.com - February 22 at 8:24 PM
News IconAre Analysts Optimistic About Where Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) is Heading? - Winfield Review (NASDAQ:AERI)
winfieldreview.com - February 22 at 8:24 PM
News IconStock Momentum Focus on Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) - Sherwood Daily (NASDAQ:AERI)
sherwooddaily.com - February 21 at 3:38 PM
News IconAnalysts Take Aim At This Stock's Earnings Estimates: Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) - Aiken Advocate (NASDAQ:AERI)
aikenadvocate.com - February 21 at 3:38 PM
News IconAnalysts Peer Into Their Crystal Balls For Aerie Pharmaceuticals, Inc. (NASDAQ:AERI): Where Is It headed? - Winfield Review (NASDAQ:AERI)
winfieldreview.com - February 21 at 6:13 AM
finance.yahoo.com logoCoverage initiated on Aerie Pharma by ROTH Capital (NASDAQ:AERI)
finance.yahoo.com - February 18 at 7:49 AM
News IconSpotting the Levels for Aerie Pharmaceuticals Inc (AERI) - Midway Monitor (NASDAQ:AERI)
midwaymonitor.com - February 17 at 3:30 PM
News IconAerie Pharmaceuticals Inc (AERI) is Initiated by ROTH Capital to ... - Highland Mirror (NASDAQ:AERI)
www.highlandmirror.com - February 17 at 3:30 PM
businesswire.com logoAerie Pharmaceuticals to Present at the RBC Capital Markets 2017 Global Healthcare Conference - Business Wire (press release) (NASDAQ:AERI)
www.businesswire.com - February 16 at 6:55 AM
finance.yahoo.com logoAerie Pharmaceuticals to Present at the RBC Capital Markets 2017 Global Healthcare Conference (NASDAQ:AERI)
finance.yahoo.com - February 16 at 6:55 AM
News IconWatching the Levels: Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) - Midway Monitor (NASDAQ:AERI)
midwaymonitor.com - February 14 at 3:36 PM
News IconStock Update for Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) - Davidson Register (NASDAQ:AERI)
davidsonregister.com - February 13 at 3:33 PM
News IconGlaucoma 2017: Controlling IOP and Promoting Adherence through Novel Therapeutics (NASDAQ:AERI)
www.healio.com - February 11 at 8:21 PM
News IconEquity Watch: Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) - Baldwin Journal (NASDAQ:AERI)
baldwinjournal.com - February 10 at 8:52 PM
finance.yahoo.com logoPost Earnings Coverage as Eli Lilly's Q4 Revenue Beat Market Estimates (NASDAQ:AERI)
finance.yahoo.com - February 10 at 3:49 PM
prnewswire.com logoHealthcare Stocks Under Scanner -- Aerie Pharma, GW Pharma, Retrophin, and SciClone Pharma - PR Newswire (press release) (NASDAQ:AERI)
www.prnewswire.com - February 9 at 3:22 PM
News IconStock Review: Level Check for Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) - Baxter Review (NASDAQ:AERI)
baxternewsreview.com - February 7 at 8:32 PM
News IconAerie Announces Appointment Of As Site Director Of New Manufacturing Plant In Ireland (NASDAQ:AERI)
www.topix.com - February 6 at 8:25 PM
reuters.com logoBRIEF-Aerie Pharmaceuticals appoints Huan Sheng as director clinical research, drug safety (NASDAQ:AERI)
www.reuters.com - February 6 at 8:25 PM
businesswire.com logoAerie Pharmaceuticals Announces Appointment of Huan Sheng, MD, Ph.D., as Director Clinical Research and Drug ... - Business Wire (press release) (NASDAQ:AERI)
www.businesswire.com - February 6 at 3:23 PM
finance.yahoo.com logoAerie Pharmaceuticals Announces Appointment of Huan Sheng, M.D., Ph.D., as Director Clinical Research and Drug Safety (NASDAQ:AERI)
finance.yahoo.com - February 6 at 3:23 PM
businesswire.com logoAerie Pharmaceuticals Announces Appointment of Barry Ivin as Site Director of New Manufacturing Plant in Ireland - Business Wire (press release) (NASDAQ:AERI)
www.businesswire.com - February 3 at 8:30 PM
uk.finance.yahoo.com logoAerie Pharmaceuticals Announces Appointment of Barry Ivin as Site Director of New Manufacturing Plant in Ireland (NASDAQ:AERI)
uk.finance.yahoo.com - February 3 at 8:30 PM
News IconOcular hypertension pipeline market with therapeutic development for H2 2016 available in new report (NASDAQ:AERI)
www.whatech.com - February 3 at 3:30 PM
News IconEarnings Parade Rolls On, What Are Analysts Saying About Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)? - Wall Street Beacon (NASDAQ:AERI)
wsbeacon.com - February 1 at 3:25 PM
News IconVolatility Watch on Shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) - The Tribune (NASDAQ:AERI)
lakecitytribune.com - January 31 at 3:32 PM
News IconVolatility Watch on Shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) - The Tribune (NASDAQ:AERI)
lakecitytribune.com - January 31 at 3:32 PM
News IconReviewing Indicator Levels for Aerie Pharmaceuticals Inc (AERI) - Springdale Times (NASDAQ:AERI)
springdaletimes.com - January 31 at 3:32 PM
News IconCould Aerie Pharmaceuticals Inc (AERI) Go Down After Achieving 52-Week High? - The Randolph Guide (NASDAQ:AERI)
randolphguide.com - January 30 at 8:33 PM
News IconHigh Volatility Moving the Needle For Shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) - Wall Street Beacon (NASDAQ:AERI)
wsbeacon.com - January 30 at 3:33 PM
News IconTrading Circle: Narrowing in on Shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) - The Tribune (NASDAQ:AERI)
lakecitytribune.com - January 30 at 1:23 AM
News IconWhat The Charts Are Saying About Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) - The Tribune (NASDAQ:AERI)
lakecitytribune.com - January 29 at 3:19 PM
News IconFollowing the Numbers on Shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) - The Tribune (NASDAQ:AERI)
lakecitytribune.com - January 28 at 3:22 PM
News IconFocus on RSI and CCI Levels: Aerie Pharmaceuticals Inc (AERI) - Springdale Times (NASDAQ:AERI)
springdaletimes.com - January 28 at 3:22 PM
thestreet.com logoDearth of Momentum Helps Build 'Wall of Worry' (NASDAQ:AERI)
realmoney.thestreet.com - January 27 at 3:48 PM
News IconEarnings in Full Force, Analysts Take Aim at Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) - Wall Street Beacon (NASDAQ:AERI)
wsbeacon.com - January 25 at 3:26 PM
News IconAerie appoints Kristine Erickson as VP, clinical research (NASDAQ:AERI)
www.poandpo.com - January 25 at 1:47 AM
News IconCompany Focus: Zooming in on Shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) - The Tribune (NASDAQ:AERI)
lakecitytribune.com - January 24 at 3:42 PM
News IconInvestor Arena: Keeping an Eye on Aerie Pharmaceuticals Inc (AERI) - Market Point (NASDAQ:AERI)
mtptnews.com - January 24 at 3:42 PM
News IconWhat is the Sell-side Saying About Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)? - Aiken Advocate (NASDAQ:AERI)
aikenadvocate.com - January 24 at 3:42 PM
businesswire.com logoAerie Pharmaceuticals Announces Appointment of Kristine Erickson, O.D., Ph.D., as Vice President Clinical Research - Business Wire (press release) (NASDAQ:AERI)
www.businesswire.com - January 23 at 8:25 PM
finance.yahoo.com logoAerie Pharmaceuticals Announces Appointment of Kristine Erickson, O.D., Ph.D., as Vice President Clinical Research (NASDAQ:AERI)
finance.yahoo.com - January 23 at 3:23 PM
News IconWhat are the Levels Showing for Shares of Aerie Pharmaceuticals Inc (AERI) - Springdale Times (NASDAQ:AERI)
springdaletimes.com - January 20 at 8:28 PM
investornewswire.com logoAerie Pharmaceuticals, Inc. (NASDAQ:AERI) Strong Sell Recommendations At 0 - Investor Newswire (NASDAQ:AERI)
www.investornewswire.com - January 20 at 8:28 PM
News IconInvestor Guide: Check on Technical Levels for Aerie Pharmaceuticals Inc (AERI) - Springdale Times (NASDAQ:AERI)
springdaletimes.com - January 16 at 3:24 PM

Social

What is Aerie Pharmaceuticals' stock symbol?

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

Where is Aerie Pharmaceuticals' stock going? Where will Aerie Pharmaceuticals' stock price be in 2017?

13 analysts have issued 1-year price objectives for Aerie Pharmaceuticals' stock. Their predictions range from $48.00 to $70.00. On average, they anticipate Aerie Pharmaceuticals' stock price to reach $56.85 in the next twelve months.

When will Aerie Pharmaceuticals announce their earnings?

Aerie Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.

What are analysts saying about Aerie Pharmaceuticals stock?

Here are some recent quotes from research analysts about Aerie Pharmaceuticals stock:

  • According to Zacks Investment Research, "Aerie is positive on the efforts in developing its pipeline candidates. Aerie has filed a new drug application (NDA) for its lead candidate, Rhopressa, in the U.S. in the Sep 2016 for treatment of glaucoma or ocular hypertension. A potential approval and successful commercialization of the drug will significantly boost the company’s growth prospects as glaucoma is one of the largest segments in the global ophthalmic market. We are also positive with Aerie’s second late-stage glaucoma candidate, Roclatan, which is being evaluated for lowering intraocular pressure in patients suffering from open-angle glaucoma and ocular hypertension. However, with no approved product in its portfolio, any regulatory setback would have an adverse impact on the stock. Estimates have remained mostly stable ahead of the company’s Q3 earnings release. However, the company has a negative record of earnings surprises in recent quarters." (11/3/2016)

  • Brean Capital analysts commented, "At yesterday’s investor day, Aerie painted a clearer portrait of the current standard of care and competitive glaucoma treatment environment. Management also provided further insight into the recent Mercury 1 data for Roclatan, a closer look at how to measure the effectiveness of glaucoma treatment with added perspective from a former physician, as well as revisited what the company’s future value adding drivers will be and articulated the international strategy. We took the opportunity to dive deeper into our model, taking into account potential future European launches and Japanese clinical trials." (10/6/2016)

  • Cantor Fitzgerald analysts commented, "Even Better: When comparing the Phase 3 results with an earlier, smaller trial, the combination drug worked even better than its ingredients. Intraocular pressure (IOP) was reduced, on average to 15-16mmHg at all nine time points measured over a 90-day period. The lowering was 1-3mmHg higher than observed with the components, latanoprost and Rhopressa. The difference, as disclosed in a slide deck presented, but not in the press release, was statistically significant with a p value of =35% reduction in IOP." (9/15/2016)

Who owns Aerie Pharmaceuticals stock?

Aerie Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Deerfield Management Co. (5.51%), Foresite Capital Management III LLC (4.79%), Foresite Capital Management II LLC (4.72%), Orbimed Advisors LLC (4.48%), State Street Corp (2.46%) and Fred Alger Management Inc. (0.75%). Company insiders that own Aerie Pharmaceuticals stock include Anand Mehra, Foresite Capital Fund Ii, LP and Geoffrey M Duyk.

Who sold Aerie Pharmaceuticals stock? Who is selling Aerie Pharmaceuticals stock?

Aerie Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, Wall Street Associates, Putnam Investments LLC, Foresite Capital Management III LLC, Foresite Capital Management II LLC, Alyeska Investment Group L.P., FMR LLC and State Board of Administration of Florida Retirement System. Company insiders that have sold Aerie Pharmaceuticals stock in the last year include Foresite Capital Fund Ii, LP and Geoffrey M Duyk.

Who bought Aerie Pharmaceuticals stock? Who is buying Aerie Pharmaceuticals stock?

Aerie Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Deerfield Management Co., State Street Corp, Genovese Burford & Brothers Wealth & Retirement Plan Management LLC, Senzar Asset Management LLC, Fred Alger Management Inc., Perceptive Advisors LLC and Russell Investments Group Ltd..

How do I buy Aerie Pharmaceuticals stock?

Shares of Aerie Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Aerie Pharmaceuticals stock cost?

One share of Aerie Pharmaceuticals stock can currently be purchased for approximately $44.55.

Aerie Pharmaceuticals (NASDAQ:AERI) Chart for Sunday, February, 26, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Earnings History Chart

Earnings by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Dividend History Chart

Dividend Payments by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Last Updated on 2/26/2017 by MarketBeat.com Staff